BMC Endocr Disord 2022 Apr 11;22(1):97. Epub 2022 Apr 11.
Department of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Dongcheng District, Key Laboratory of Endocrinology of National Health Commission, Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, No. 1 Shuaifuyuan, PekingBeijing, 100730, China.
Background: Recently, side effects from Dopamine Receptor Agonist Drugs (DAs) in treating pituitary prolactinoma have raised widespread concern. This study explores the incidence and influencing factors of DAs-related side effects in Chinese prolactinoma patients.
Methods: A cross-sectional study was conducted. Read More